Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis

Eric J Lowe1, Ching-Hon Pui, Michael L Hancock

  • 1Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA. eric.lowe@stjude.org

Pediatric Blood & Cancer
|November 18, 2004
PubMed

Insights

Serious complications from hyperleukocytosis in childhood acute lymphoblastic leukemia (ALL) are uncommon and often present at diagnosis. Management strategies should consider leukocyte counts and presenting symptoms.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Leukemia Research

Background:

  • Optimal management for childhood acute lymphoblastic leukemia (ALL) with hyperleukocytosis remains unclear.
  • The risk of leukostasis-related complications in this patient group is not well-characterized.

Purpose of the Study:

  • To characterize the frequency and type of complications in children with ALL and hyperleukocytosis.
  • To evaluate the impact of initial leukocyte count on complication risk.
  • To assess the role of cytoreduction in managing hyperleukocytosis.

Main Methods:

  • Retrospective review of 178 children with previously untreated ALL and leukocyte count >200 x 10(9)/L.
  • Analysis of presenting characteristics, management, and complications.
  • Statistical analysis to determine predictors of complications.

Main Results:

  • 9% of patients experienced neurological complications, and 2% had CNS hemorrhage.
  • Pulmonary leukostasis occurred in 6% of patients.
  • Higher leukocyte counts significantly predicted neurological and respiratory complications, mostly occurring at presentation.

Conclusions:

  • Serious leukostasis-related complications are uncommon in childhood ALL, increasing with leukocyte count.
  • Most complications occur at presentation.
  • Cytoreduction may be beneficial for patients with leukocyte counts >400 x 10(9)/L or presenting complications, but can delay chemotherapy initiation.
Abstract